Guardant Health raised its full-year 2026 guidance after Q1 revenue grew 48% year over year, driven by continued strength in oncology testing and screening. The company reported $301.7 million total revenue in Q1 versus $203.5 million a year earlier and increased its full-year guidance range to $1.30 billion to $1.32 billion. Guardant attributed the performance to volume growth in minimal residual disease and oncology testing, including a 47% year-over-year increase in oncology test volumes to 86,000 units. CEO Helmy Eltoukhy also highlighted growth in Guardant360 liquid volumes and an upgrade to Guardant360 Tissue to include whole-transcriptome RNA testing, which the company expects to act as a volume catalyst. Guardant said it has submitted data packages to CMS’s MolDx program across multiple settings, including breast cancer surveillance, immunotherapy monitoring, and chemotherapy monitoring—potential reimbursement milestones for liquid biopsy products.